Want the good news first, or the bad news? How about the great news? The Food and Drug Administration released the data on Moderna’s emergency-use authorization (EUA) for its COVID-19 vaccine this morning, and it has nothing but great news. The two-dose regimen results in 94% efficacy in producing an immune response against the virus, almost identical to that of Pfizer. Even on the first dose, the efficacy rate would normally satisfy FDA approval requirements.
Unlike Pfizer’s vaccine trials, however, Moderna has evidence that its vaccine can stop people from spreading the virus as well:
Moderna’s Covid-19 vaccine is 94 percent effective at preventing symptomatic illness and appears to prevent the spread of the virus as well, according to documents released Tuesday. …
The high efficacy of the Moderna vaccine was noted after two doses given 28 days apart. This is about the same level of effectiveness as the Pfizer-BioNTech vaccine.
But there is also evidence that just one dose of Moderna’s may stop the virus’s spread. A second document published on the FDA website shows asymptomatic infection was reduced by 63 percent after the first shot.